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Abstract
Background—Cigarette smoking is an established predictor of incident type 2 diabetes mellitus, 
but the effects of smoking cessation on diabetes risk are unknown.
Objective—To test the hypothesis that smoking cessation increases diabetes risk in the short 
term, possibly due to cessation-related weight gain.
Design—Prospective cohort study.
Setting—The Atherosclerosis Risk in Communities (ARIC) study.
Patients—10,892 middle-aged adults who initially did not have diabetes in 1987 to 1989.
Measurements—We assessed smoking by interview at baseline and at subsequent follow-ups. 
Incident diabetes was ascertained by fasting glucose assays through 1998 and self-report of 
physician diagnosis or use of diabetes medications through 2004.
Results—During 9 years of follow-up, 1,254 adults developed type 2 diabetes. Compared with 
adults who never smoked, the adjusted hazard ratio of incident diabetes in the highest tertile of 
pack-years was 1.42 (95% CI, 1.20 to 1.67). In the first 3 years of follow-up, 380 adults quit 
smoking. After adjustment for age, race, sex, education, adiposity, physical activity, lipids, blood 
pressure, and ARIC center, compared with adults who never smoked the hazard ratio of diabetes 
among former smokers, new quitters, and continuing smokers were 1.22 (CI, 0.99 to 1.50), 1.73 
(CI, 1.19 to 2.53), and 1.31 (CI, 1.04 to 1.65), respectively. Further adjustment for weight change 
and leukocyte count attenuated these risks substantially. In an analysis of long-term risk after 
quitting, the highest risk occurred in the first 3 years (hazard ratio, 1.91 [CI, 1.19 to 3.05]), then 
gradually decreased to 0 at 12 years.
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Limitation—Residual confounding is possible even with the most meticulous adjustment for 
established diabetes risk factors.
Conclusion—Cigarette smoking predicts incident type 2 diabetes, but smoking cessation leads 
to higher short-term risk. For smokers at risk for diabetes, smoking cessation should be coupled 
with strategies for diabetes prevention and early detection.
An extensive body of literature (1) consistently identifies cigarette smoking as a risk factor 
for incident diabetes. Therefore, smoking cessation should decrease diabetes risk among 
current smokers, perhaps by reducing systemic inflammation, which is a well-established 
risk factor for incident diabetes (2). However, smoking cessation is also associated with 
substantial weight gain (3), which could tip the balance toward increased risk. Few studies 
(4–7) have investigated metabolic changes or diabetes risk after smoking cessation. We 
therefore analyzed longitudinal data from the ARIC (Atherosclerosis Risk in Communities) 
study, a biracial, community-based study of 15,792 middle-aged adults, to test the 
hypothesis that, although smoking is an independent predictor of incident type 2 diabetes, 




The ARIC study is an ongoing prospective cohort study designed to assess subclinical and 
clinical atherosclerosis in a cohort of adults aged 45 to 64 years who were selected by using 
probability sampling from the following 4 U.S. communities: Forsyth County, North 
Carolina; Jackson, Mississippi; the northwestern suburbs of Minneapolis, Minnesota; and 
Washington County, Maryland. By design, the Jackson site exclusively recruited African 
Americans, thereby accounting for about 90% of African Americans in the study. Most of 
the remaining African Americans came from the Forsyth County cohort. The sampling 
procedure and methods used in the ARIC study have been described elsewhere (8). Our 
study was based on 17-year follow-up data, including a baseline visit from 1987 through 
1989, 3 follow-up clinic visits scheduled approximately 3 years apart (ARIC Visits 2 to 4, 
1990 to 1998), and annual telephone contacts thereafter up to 2004. Institutional review 
boards of all participating institutions approved the study protocols.
Composition of the Study Cohort
For the primary analyses during 9 years of follow-up through visit 4, we excluded persons 
on the basis of 1 of the following criteria (persons can be excluded for multiple reasons): 
ethnicity other than black or white (n = 48), preexisting diabetes at baseline (n = 1,870), 
missing data on smoking or diabetes status at baseline (n = 394), no follow-up or incomplete 
incident diabetes information (n = 1,147), missing data on relevant baseline covariates (n = 
85), self-reported asthma or chronic lung disease (n = 1,704), or prevalent heart disease (n = 
807). The study sample consisted of 10,892 adults without diabetes at baseline (Figure 1). 
To further study the change of smoking status from baseline to 3-year follow-up and the risk 
for diabetes at later follow-up clinic visits, we excluded persons who had incident diabetes at 
the 3-year follow-up (n = 769) in whom smoking data were missing at the time (n = 232), 
Yeh et al. Page 2













who were new or relapsed smokers (n = 378), in whom reporting on smoking status was 
inconsistent (n = 151), or in whom data on weight were missing (n = 224). Therefore, we 
included 9,398 adults without diabetes at baseline or 3-year follow-up for this part of the 
analysis.
In the supplementary analysis of long-term risk up to 2004, we used only self-reported 
information from clinic visits (1987 to 1998) and telephone interviews (1999 to 2004) to 
define incident cases (that is, physician diagnosis or use of diabetes medications), resulting 
in 10,406 at-risk adults without diabetes at baseline and 3-year follow-up.
Smoking Assessment
We assessed smoking status (current smokers, former smokers, or persons who never 
smoked) by interview at baseline and at subsequent follow-up clinic visits. We asked 
smokers (current or former) the average number of cigarettes smoked daily during the time 
they smoked. We calculated pack-years of smoking as the average number of cigarettes per 
day times the years of smoking, divided by 20. We calculated years since quitting before 
baseline as baseline age minus the recalled age of quitting. In analyses regarding change of 
smoking status from baseline to 3-year follow-up, we characterized smoking status as never- 
smoker, former smoker at baseline, new quitter (smoker at baseline but former smoker at 
follow-up), and continuing smoker (smoker at both baseline and follow-up).
Incident Type 2 Diabetes Mellitus
We classified persons as having diabetes if they met any of the following criteria, adapted 
from 1997 American Diabetes Association criteria: fasting glucose level of at least 7.0 
mmol/L (126 mg/dL); nonfasting glucose level of at least 11.1 mmol/L (200 mg/L); current 
use of diabetes medication; or a positive response to the question, “Has a doctor ever told 
you that you had diabetes (sugar in the blood)?” In the primary analysis based on fasting 
glucose level and self-report, fasting glucose level was available for more than 95% of 
participants at each of the 4 clinic visits (1987 to 1998), regardless of smoking status. 
According to customary practice, persons who met criteria for diabetes on a single occasion 
were considered to have diabetes for the remainder of follow-up, regardless of subsequent 
changes in interview responses or glucose level.
Other Baseline Variables
Information on age, sex, race, education level, and family history of diabetes was based on 
self-report. We assessed physical activity by using a modified version of the questionnaire 
developed by Baecke and colleagues (9), from which we derived a sport index, ranging from 
1 (lowest) to 5 (highest). We measured weight, height, waist circumference, and blood 
pressure by standardized procedures (10). We determined systolic and diastolic blood 
pressure as the mean of the second and third of 3 standardized measurements by using a 
random-zero sphygmomanometer after 5 minutes of rest (11). We asked participants to fast 
for at least 8 hours before morning blood collection. We assessed serum glucose level by a 
modified hexokinase-glucose-6-phosphate dehydrogenase procedure. We measured total 
triglyceride level (12) by enzymatic methods and high-density lipoprotein (HDL) cholesterol 
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level after dextran-magnesium precipitation (13). We measured leukocyte count locally by 
automated cell counters (14).
Statistical Analysis
We first grouped participants by cumulative pack- years assessed at baseline. Distribution of 
pack-years among smokers was approximately normal and was categorized into tertiles. 
Adults who never smoked comprised the reference group. We determined means and 
frequencies of potential confounders assessed at baseline for each smoking category. We 
used analysis of variance F test and Pearson chi-square test to assess the statistical 
significance of the differences across the 4 smoking categories. We used linear regression 
and chi-square test for trend to assess the significance level for linear trend.
We calculated incidence rates of diabetes for each smoking category by using a person-years 
approach. For participants without diabetes, we calculated person-years from baseline to the 
last clinic visit date. For participants with incident diabetes, we assigned the date of 
occurrence according the method described by Duncan and colleagues (15) as the date when 
fasting glucose level reached the diagnostic threshold of 7 mmol/L (26 mg/dL), estimated 
with linear interpolation. We used Cox proportional hazards models for multivariable 
analysis to derive adjusted hazards for incident diabetes by categories of smoking status 
compared with persons who never smoked. We adjusted all multivariable Cox models for 
race, sex, ARIC center, education, baseline age, body mass index (BMI), waist 
circumference, physical activity index, triglyceride level, HDL cholesterol level, and systolic 
blood pressure. We confirmed the proportionality assumption by examining Schoenfeld 
residuals (16). We used the Efron method (17) to handle ties.
To assess effects of smoking cessation on diabetes risk, we calculated years since quitting in 
former smokers (baseline age minus recalled age at the time of quitting), then stratified the 
study population into 6 smoking categories: never-smokers, former smokers (4 categories), 
and current smokers. Next, we prospectively investigated changes in metabolic features as 
well as risk for diabetes at the 6- and 9-year follow-up visits in 9,398 participants associated 
with change of smoking status from baseline to 3-year follow-up (visit 2). We classified 
smoking status into 4 categories: persons who never smoked, persons who did not resume 
smoking through visit 2, persons who smoked at baseline but quit smoking by visit 2 (new 
quitters), and persons who continued smoking through visit 2. We estimated the associations 
between smoking categories and incidence diabetes in both sets of analyses by using Cox 
models.
We assessed the relation between change of smoking status and selected metabolic variables
—including baseline values as well as changes in weight, waist circumference, fasting 
glucose level, total triglyceride level, HDL cholesterol level, systolic and diastolic blood 
pressure, and leukocyte count - by using a series of linear regression models that adjusted for 
sex, race, age, physical activity index (scale of 1 [lowest] to 5 [highest]), educational level, 
and ARIC center. We further adjusted for baseline values of the variable of interest and exact 
time interval between baseline and 3-year follow-up when studying changes in metabolic 
variables. We used multivariable linear regression models to obtain adjusted means and 
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mean differences between smoking categories and the never-smokers group, as well as 
corresponding p values and CIs.
To investigate possible mediators of cessation-related diabetes risk, we performed additional 
multivariable analyses by using the Cox model to investigate 2 possible mediators: weight 
gain (baseline to visit 2) and leukocyte count at baseline—an indicator of smoking-induced 
systemic inflammation. First, we separately adjusted for weight gain and leukocyte count; 
we then simultaneously adjusted for both into a model that already included race, sex, ARIC 
study center, level of education, baseline age, BMI, waist circumference, physical activity, 
triglyceride level, HDL cholesterol level, and systolic blood pressure.
To explore the potential of using readily available characteristics to identify high-risk 
subgroups among new quitters in primary care settings, we conducted post hoc analyses of 
diabetes risk (as compared with persons who never smoked) associated with various 
demographic (age, race, and sex), anthropometric (weight change), and behavioral 
(cigarettes per day) factors. We dichotomized continuous variables on the basis of 
distributional or conventional cutoffs. Older age, heavier smoking before quitting, and 
greater weight gain after quitting were believed to impose higher risk among new quitters. 
We first stratified analyses by sex and race. We subsequently combined categories with 
similar risks to allow fewer subgroups and more stable hazard estimates through 
multivariable Cox regression modeling after adjustment for other potential covariates.
To extend estimation of long-term trends in diabetes risk associated with smoking and 
smoking cessation through 17 years of follow-up, we conducted supplementary analyses, 
including self-reported data from follow-up telephone interviews from 1999 through 2004. 
To maintain consistency in outcome assessment, this supplementary analysis incorporated 
self-reported data only from the clinic visits (1987 through 1998) and ignored available data 
on fasting glucose level. To be consistent with the approximate 3-year interval between 
follow-up clinic visits, we abstracted smoking status and incident diabetes cases every 3 
years from the annual telephone interviews and calculated the risks for up to 12 years after 
the participant quit. We assumed incident cases occurred at the midpoint between the last 
visit or phone call at which diabetes was reported to be absent and the first visit or phone 
call at which diabetes was found. This approach has been used in other ARIC publications 
(18, 19).
Like most reports based on observational studies, ours did not apply multiplicity adjustments 
for the number of statistical tests conducted. However, the primary analyses were based on a 
priori hypotheses, and most statistical tests were done to identify potential confounders and 
mediators for the observed associations of incident diabetes risk with smoking and smoking 
cessation.
Tests of significance were 2-tailed, with an α level of 0.05. We performed analyses by using 
SAS, version 9.1 (Cary, North Carolina), and Stata/SE, version 10.0 (College Station, 
Texas).
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Table 1 shows baseline characteristics of 10,892 adults who initially did not have diabetes, 
stratified by pack-years of smoking. Persons with higher cumulative smoking exposure were 
significantly more likely to be male, white, and less educated and to have a higher leukocyte 
count and waist-to-hip ratio but lower BMI (all p for linear trend < 0.001).
Incident Type 2 Diabetes
During 9 years of follow-up, 1,254 adults developed type 2 diabetes. A graded relationship 
existed between pack-years of smoking and incidence rates of type 2 diabetes. Diabetes 
incidence rose from 13.3 per 1,000 person-years in persons who never smoked to 18.5 per 
1.000 person-years in the highest tertile of pack-years, corresponding to an age- and race-
adjusted relative risk for 1.40 (95% CI, 1.20 to 1.64). In multivariable analyses using Cox 
proportional hazards models, the significant, graded association between pack-years and 
incidence of diabetes persisted after adjustment for race, sex, ARIC study center, level of 
education, baseline age, BMI, waist circumference, physical activity, triglyceride level, HDL 
cholesterol level, and systolic blood pressure. Compared with persons who never smoked, 
the adjusted hazard ratio of diabetes among persons who smoked no more than 13 pack-
years, 14 to 30 pack-years, and more than 30 pack-years were 1.09 (CI, 0.92 to 1.28), 1.38 
(CI, 1.18 to 1.61), and 1.42 (CI, 1.20 to 1.67), respectively (Appendix Figure).
Smoking Cessation and Diabetes Risk
After adjustment for race, sex, ARIC study center, level of education, baseline age, BMI, 
waist circumference, physical activity, triglyceride level, HDL cholesterol level, and systolic 
blood pressure, compared with participants who never smoked, the adjusted hazard ratios of 
incident diabetes during 9 years of follow-up were 1.16 (CI, 0.99 to 1.36), 1.21 (CI, 0.89 to 
1.65), 1.54 (CI, 1.10 to 2.14), 1.80 (CI, 1.44 to 2.25), and 1.26 (CI, 1.08 to 1.46) in former 
smokers who quit more than 9 years before the baseline visit, 6 to 9 years before, 3 to 6 
years before, and within 3 years before and in current smokers, respectively (Figure 2).
From baseline to the 3-year clinic visit, 380 participants quit smoking and 2,018 participants 
continued to smoke. Compared with their counterparts who continued to smoke, those who 
quit had significantly fewer pack-years of smoking (28 vs. 31; p < 0.001) and lower 
leukocyte counts (7.0 × 109 cells/L vs. 7.2 × 109 cells/L; p = 0.017) at baseline, but no 
significant differences existed in sex (p = 0.48), race (p = 0.159), age (p = 0.156), level of 
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education (p = 0.106), parental history of diabetes (p = 0.146), physical activity (p = 0.92), 
BMI (p = 0.26), waist-to-hip ratio (p = 0.86), or percentage of hypertension (p = 0.68) for 
baseline comparisons).
In multivariable linear regression models adjusting for sex, race, baseline age, physical 
activity, educational level, and ARIC center (Appendix Table), adults who quit smoking 
between baseline and visit 2, compared with their counterparts who never smoked, had 
significantly lower body weight, smaller waist circumference, lower HDL cholesterol level, 
higher triglyceride level, lower blood pressure, and higher leukocyte count at baseline. 
Prospectively, these new quitters, compared with persons who never smoked, had more 
significant increases in weight, waist circumference, and fasting glucose. They also had a 
small but statistically significant decrease in leukocyte count (p = 0.001). On the other hand, 
persons who continued to smoke, compared with those who never smoked, displayed less 
gain in weight and waist circumference, greater decreases in diastolic blood pressure and 
HDL cholesterol level, and a greater increase in leukocyte count.
In multivariable analyses using the Cox proportional hazards models, compared with 
persons who had never smoked, the adjusted hazard ratios of diabetes among former 
smokers at baseline, new quitters, and continuing smokers were 1.22 (CI, 0.99 to 1.51), 1.73 
(CI, 1.19 to 2.53), and 1.31 (CI, 1.04 to 1.65), respectively, after adjustment for race, sex, 
ARIC study center, level of education, baseline age, BMI, waist circumference, physical 
activity, triglyceride level, HDL cholesterol level, and systolic blood pressure (Table 2, 
Model 1).
Possible Mediators of Diabetes Risk
Adjustment for weight gain partially explained excess risk in new quitters, but did not 
account for excess risk in continuing smokers (Table 2, Model 2). Adjustment for leukocyte 
count attenuated the risk relationships in both new quitters and continuing smokers (Table 2, 
Model 3). When simultaneously adjusted for both possible mediators, diabetes risk was 
markedly attenuated in new quitters and continuing smokers but essentially unchanged in 
former smokers (Table 2, Model 4).
Identification of High-Risk Subgroup Among New Quitters
We conducted a series of post hoc analyses to identify high-risk subgroups of new quitters 
by using various categories of sex, race, age, weight change, and cigarettes per day. 
Compared with persons who never smoked, male new quitters with the highest diabetes risk 
seemed to be those who were aged 60 years or older at visit 2, smoked 20 or more cigarettes 
per day before quitting, and gained more than 4 kg between baseline and visit 2 (hazard 
ratio, 3.44 [CI, 1.07 to 11.04]), followed by men younger than 60 years who had the same 
smoking and weight gain experiences (hazard ratio, 2.28 [CI, 1.05 to 4.93]). Male quitters 
who, regardless of age, smoked 20 or more cigarettes per day before quitting but did not 
gain more than 4 kg between baseline and visit 2 also had increased, although not 
statistically significant, risk (hazard ratio, 1.96 [CI, 0.79 to 4.82]). Among female new 
quitters, those who smoked fewer than 20 cigarettes per day before quitting but gained more 
than 4 kg between baseline and visit 2 were associated with the highest diabetes risk (hazard 
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ratio, 2.69 [CI, 1.25 to 5.79]). We did not find statistically significantly increased risk in 
other subgroups, which in part may be due to the modest sample size of the new-quitters 
group.
Supplementary Analysis on Long-Term Risk After Quitting
In this set of analyses, we calculated hazard ratios (Figure 3) based on self-reported diabetes 
through 2004. The highest diabetes risk in quitters occurred during the first 3 years after 
quitting (hazard ratio, 1.89 [CI, 1.26 to 2.82]), then gradually decreased until no excess risk 
was seen at 12 years. In contrast, risk for diabetes in continuing smokers remained flat 
during extended follow-up, with hazard ratios ranging from 0.93 (CI, 0.71 to 1.22) to 1.10 
(CI, 0.78 to 1.56).
DISCUSSION
In this prospective study of middle-aged men and women, greater cumulative exposure to 
cigarette smoking predicted development of type 2 diabetes. As expected, the association 
was graded and was independent of many potentially confounding factors. However, 
smoking cessation did not seem to reduce this risk; on the contrary, adults who quit smoking 
experienced relatively more adverse changes in their metabolic profile and an increased risk 
for incident diabetes, peaking within 3 years of quitting, but still observable 6 years after 
quitting. The increased risk seemed to be partially mediated by weight gain and systemic 
inflammation.
Our finding of a 40% increase in hazard ratio for smokers is similar to that of a recent meta-
analysis (1) of 25 prospective cohort studies with follow-up ranging from 5 to 30 years, 
which reported pooled adjusted relative risk for diabetes of 1.44 (CI, 1.31 to 1.58) for 
current smokers compared with nonsmokers. The gradient across the intensity of smoking 
exposure is similar. In the meta-analysis, the risk for diabetes was greater for heavy smokers 
(> 20 cigarettes/day; relative risk, 1.61 [CI, 1.43 to 1.80]) than for lighter smokers (relative 
risk, 1.29 [CI, 1.13 to 1.48]) or former smokers (relative risk, 1.23 [CI, 1.14 to 1.33]) 
compared with continued smokers. However, the meta-analysis did not address the effects of 
smoking cessation.
After searching MEDLINE for all pertinent literature published in English until January 
2009 using keywords “diabetes” and “cessation,” we found few studies that investigated 
smoking cessation and changes in metabolic profiles. Balkau and colleagues (4) analyzed 
data from 1,958 men and 2,028 women, aged 30 to 65 years, who were in the DESIR (Data 
from an Epidemiological Study on the Insulin Resistance Syndrome) cohort. The authors 
observed that a reduction of 10 cigarettes per day over 3 years was associated with 
significant increases in insulin (7%), glucose (0.11 mmol/L [1.98 mg/dL]), triglyceride level 
(8%), waist circumference (0.97 cm), and BMI (0.31 kg/m2) in men and significant 
increases in HDL cholesterol level (0.06 mmol/L [2.32 mg/dL]), waist circumference (1.1 
cm), and BMI (0.59 kg/m2) in women. Although our results are presented in a different 
format, we found a similar spectrum of adverse metabolic changes in adults who quit 
smoking entirely.
Yeh et al. Page 8













Only 2 studies (6, 7) have investigated smoking cessation in relation to diabetes risk. In 
7,124 men in the British Regional Heart Study who initially did not have diabetes, 
Wannamethee and colleagues (6) found that men who quit smoking in the first 5 years of 
follow-up had significant weight gain (mean weight gain, 9.4 kg vs. 7.1 kg in persons who 
never smoked) and subsequently higher risk for diabetes than persons who never smoked 
(adjusted relative risk, 2.03 [CI, 1.22 to 3.37]). More recently, Hur and colleagues (7) 
reported on 27,635 Korean men aged 35 to 44 years who initially did not have diabetes and 
who were members of the Korean Medical Insurance Corporation Study cohort. In this 
cohort, compared with nonsmokers, men who quit smoking in the past 2 to 6 years had a 2-
fold increased risk for diabetes (relative risk, 2.13 [CI, 1.51 to 3.00]). However, our study 
expanded on the short-term deleterious changes in diabetes risk factors found with quitting: 
In addition to large weight gain, we observed large gains in waist circumference and 
sustained elevation of inflammation, as indicated by leukocyte count.
Our study suggests that heavy smokers with evidence of systemic inflammation who gain 
substantial weight after quitting are at the highest risk for diabetes. Past studies have found a 
link between inflammation and rapid fatty tissue deposition (20), obesity (especially in 
quitters) (21), insulin resistance (22), lipoprotein metabolism (23), and glucose homeostasis 
(24). Heavy smoking is also a marker of nicotine exposure. Withdrawal of nicotine may lead 
to increased appetite and excess caloric intake (25).
We were surprised that continuing smokers experienced only a small excess risk for diabetes 
during extended follow-up, despite the inflammatory burden imposed by smoking. A 
possible explanation is that nicotine and its metabolites, through −7 nicotinic acetylcholine 
receptors, may exert anti-inflammatory effects. These effects have been documented 
elsewhere in leukocyte cells and adipocytes, both in vitro (26, 27) and in vivo (28, 29).
Strengths of our study include a community-based sampling method; a biracial cohort; 
availability of blood measurements; extensive data on potential confounders; a large sample 
size, which increased precision and permitted simultaneous statistical adjustment for 
multiple variables; and up to 17 years of follow-up, which offered the opportunity to study 
long-term effects, including changes in smoking exposure. Nevertheless, several limitations 
deserve mention. First, like most epidemiologic studies of type 2 diabetes, we did not 
require consistent glucose elevation or repeated confirmations of diabetes self-report to 
classify persons as having diabetes: Once criteria were met on a single occasion, persons 
were considered to have diabetes for the remainder of follow-up. To the extent that this 
convention reduced the specificity of diabetes classification, it may have led us to 
underestimate the strength of the associations we observed. Second, in the supplementary 
analysis, we based ascertainment of diabetes and smoking status on telephone interviews. 
Data obtained from telephone interviews may not have been equivalent to those obtained in 
face-to-face interviews at clinic visits. Second, smokers might be underrepresented in later 
years of follow-up due to higher mortality or lower response rates. Third, given the strong 
relation between type 2 diabetes and central adiposity, even the most meticulous adjustment 
for BMI and waist circumference leaves some possibility of residual confounding. Fourth, 
an observational study cannot prove causality. Quitters may have been at inherently higher 
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risk for diabetes before quitting, although we have accounted for a wide range of established 
diabetes risk factors, including age, BMI, physical activity, and lipids.
Our study has 2 main implications. First, despite the well-established association of 
cumulative smoking with long-term diabetes risk, smoking cessation does not seem to 
reduce the short-term risk for diabetes but increases it. Of course, smoking cessation has 
many beneficial health effects that outweigh this short-term risk. Nonetheless, physicians 
should be aware of this elevated risk and should consider countermeasures, especially for 
heavy smokers. Such countermeasures might include lifestyle counseling and aggressive 
weight management, use of nicotine replacement therapy—which seems to blunt weight 
gain related to quitting (30)—and more frequent checking of blood glucose as a means of 
early detection. Second, our results imply that smoking prevention should be superior to 
smoking cessation as a means of reducing smoking-related risk for diabetes in the general 
population.
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APPENDIX
Figure 1. 
Nine-year adjusted hazard ratio (1990–1998) for incident diabetes in 10,892 middle-aged 
adults by tertile of pack-years of smoking at baseline (1987–1989). Estimates are 
simultaneously adjusted for race, sex, ARIC study center, level of education, baseline age, 
body mass index, waist circumference, physical activity, triglycerides, HDL cholesterol, and 
systolic blood pressure. Bars indicate 95% confidence intervals. Never-smokers comprise 
the reference group. Summary relative hazards [95%CI] were estimated in a model in which 
pack-years were handled as a continuous variable.
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Individuals may have met more than 1 exclusion criteria.
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Nine-year adjusted hazard ratio (1990–1998) for incident diabetes in 10,892 middle-aged 
adults by years of quitting before baseline (1987–1989). Estimates are simultaneously 
adjusted for race, sex, ARIC Study center, level of education, baseline age, body mass index, 
waist circumference, physical activity, triglycerides, HDL cholesterol, and systolic blood 
pressure. Bars indicate 95% confidence intervals. Never-smokers comprise the reference 
group.
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Figure 3. Adjusted hazard ratios for incident self-reported diabetes over 12 years by smoking 
status in 10,406 middle-aged adults without diabetes at baseline and 3-year follow-up
The diamonds connected by the solid line represents hazard ratios of adults who quit 
smoking between baseline (Visits 1, 1987–89) and Visit 2 (1990–1992), and continued 
cessation up to the interval prior to the clinic follow-up visits or telephone interviews where 
hazard ratios were estimated. The circles connected by the dotted line represents hazard 
ratios of smokers who continued smoking up to the prior interval. Non-smokers comprise 
the reference group (not depicted on the graph). Estimates are simultaneously adjusted for 
race, sex, ARIC study center, level of education, baseline age, body mass index, waist 
circumference, physical activity, triglycerides, HDL cholesterol, and systolic blood pressure. 
The bars indicate upper and lower confidence intervals; (for the sake of clarity, only one 
interval is shown for each estimate).
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